8-K: Precision BioSciences Reports $108.5 Million Cash Balance, Extends Runway into Second Half of 2026

Precision BioSciences anticipates a cash balance of $108.5 million at the end of 2024 and expects its cash runway to extend into the second half of 2026.

Summary

• Precision BioSciences estimates it had approximately $108.5 million in cash, cash equivalents, and restricted cash as of December 31, 2024, before a $2.5 million payment from TG Therapeutics and other cash inflows in January 2025.
• This cash balance is preliminary and unaudited, and the final audited results may differ.
• The company expects its existing cash, potential near-term cash from CAR T transactions, operational receipts, fiscal discipline, and its at-the-market (ATM) facility to extend its cash runway into the second half of 2026.
• Precision BioSciences believes it has sufficient capital to advance two wholly owned programs through Phase 1 data readouts in 2025 and 2026.
• The company received a $2.5 million deferred cash payment from TG Therapeutics on January 6, 2025, and issued 220,712 shares of its common stock to TG Subsidiary.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a strong cash position and extended runway, but also acknowledges risks and uncertainties. The sentiment is cautiously optimistic.

Positives

• The company has a strong cash position of $108.5 million at the end of 2024.
• The cash runway is expected to extend into the second half of 2026, providing financial stability.
• The company received a $2.5 million payment from TG Therapeutics, further bolstering its cash reserves.
• Precision BioSciences is sufficiently capitalized to advance two key programs through Phase 1 data readouts.

Negatives

• The reported cash balance is preliminary and unaudited, and the final audited results may differ.
• The company's future success depends on securing additional funding or partnership opportunities.

Risks

• The company's ability to secure sufficient funding or partnerships is uncertain.
• The success of the company's programs and product candidates is not guaranteed.
• Other genome-editing technologies may provide significant advantages over the company's ARCUS technology.
• The company's ability to advance product candidates into and complete clinical trials is subject to risk.
• The success of existing and future collaboration agreements is not guaranteed.

Future Outlook

The company expects its cash runway to extend into the second half of 2026 and plans to advance two wholly owned programs through Phase 1 data readouts in 2025 and 2026.

Management Comments

• The company believes it is sufficiently capitalized to propel two wholly owned programs through Phase 1 data readouts in 2025 and 2026.

Industry Context

This announcement is relevant to the biotechnology industry, particularly companies focused on gene editing and CAR T therapies. The cash runway extension is a positive sign for the company's ability to continue its research and development efforts.

Comparison to Industry Standards

• It is difficult to make a direct comparison without knowing the specific burn rate of Precision BioSciences and the cash runway of similar companies.
• Companies like CRISPR Therapeutics and Editas Medicine are also in the gene editing space, but their financial situations and program timelines may differ significantly.
• The $108.5 million cash balance is a reasonable amount for a company at this stage, but the key will be how efficiently they use the funds to achieve clinical milestones.

Related Party Transactions

• The company received a $2.5 million payment from TG Therapeutics and issued 220,712 shares of common stock to TG Subsidiary.

Stakeholder Impact

• Shareholders will likely view the extended cash runway and progress on clinical programs positively.
• Employees may feel more secure about the company's financial stability.
• Customers and partners may have increased confidence in the company's ability to deliver on its commitments.

Next Steps

• The company will continue to advance its two wholly owned programs through Phase 1 data readouts in 2025 and 2026.
• The company will continue to seek additional funding or partnership opportunities.
• The company will finalize its financial results for the year ended December 31, 2024.

Key Dates

Keywords

Precision BioSciences, cash runway, CAR T therapy, gene editing, clinical trials, financial results, ARCUS technology, TG Therapeutics, Phase 1 data